AKT1 and type 2 diabetes mellitus: Our study corroborated that ApoE4 exacerbated insulin signaling deficits in T2DM mice, specifically by inhibiting AKT Ser473 phosphorylation and reducing GSK‐3β Ser9 phosphorylation.